Liquidia (LQDA) said Monday that United Therapeutics (UTHR) has filed a complaint Friday accusing the company of infringing United's patent.
The complaint, filed in the US District Court for the Middle District of North Carolina, also seeks to enjoin Liquidia from commercializing Yutrepia, or treprostinil inhalation power, if the US Food and Drug Administration approves it for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Liquidia Chief Executive Roger Jeffs said the company has previously invalidated similar claims covering the treatment of pulmonary hypertension patients with inhaled treprostinil.
The company said United Therapeutics is not currently seeking an injunction against the FDA, which had set a Prescription Drug User Fee Act goal date of May 24 to prevent final approval of the new drug application for Yutrepia.
United Therapeutics did not immediately respond to a request for comment from MT Newswires.
Price: 15.46, Change: +0.20, Percent Change: +1.31
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.